186 related articles for article (PubMed ID: 34636896)
1. Approach to the Patient: Safety of Growth Hormone Replacement in Children and Adolescents.
Bamba V; Kanakatti Shankar R
J Clin Endocrinol Metab; 2022 Feb; 107(3):847-861. PubMed ID: 34636896
[TBL] [Abstract][Full Text] [Related]
2. Hormone replacement therapy in children: The use of growth hormone and IGF-I.
Pfäffle R
Best Pract Res Clin Endocrinol Metab; 2015 Jun; 29(3):339-52. PubMed ID: 26051295
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
[TBL] [Abstract][Full Text] [Related]
4. Current indications for growth hormone therapy for children and adolescents.
Richmond E; Rogol AD
Endocr Dev; 2010; 18():92-108. PubMed ID: 20523020
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
Maghnie M; Ranke MB; Geffner ME; Vlachopapadopoulou E; Ibáñez L; Carlsson M; Cutfield W; Rooman R; Gomez R; Wajnrajch MP; Linglart A; Stawerska R; Clayton PE; Darendeliler F; Hokken-Koelega ACS; Horikawa R; Tanaka T; Dörr HG; Albertsson-Wikland K; Polak M; Grimberg A
J Clin Endocrinol Metab; 2022 Nov; 107(12):3287-3301. PubMed ID: 36102184
[TBL] [Abstract][Full Text] [Related]
6. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center.
Al Shaikh A; Daftardar H; Alghamdi AA; Jamjoom M; Awidah S; Ahmed ME; Soliman AT
Acta Biomed; 2020 Mar; 91(1):29-40. PubMed ID: 32191651
[TBL] [Abstract][Full Text] [Related]
7. Growth hormone prescribing patterns in the UK, 2013-2016.
Shepherd S; Saraff V; Shaw N; Banerjee I; Patel L
Arch Dis Child; 2019 Jun; 104(6):583-587. PubMed ID: 30567827
[TBL] [Abstract][Full Text] [Related]
8. Reduced Effectiveness and Comparable Safety in Biweekly
Sun C; Lu B; Liu Y; Zhang Y; Wei H; Hu X; Hu P; Zhao Q; Liu Y; Ye K; Wang K; Gu Z; Liu Z; Ye J; Zhang H; Zhu H; Jiang Z; Liu Y; Wan N; Yan C; Yin J; Ying L; Huang F; Yin Q; Xi L; Luo F; Cheng R
Front Endocrinol (Lausanne); 2021; 12():779365. PubMed ID: 34899612
[TBL] [Abstract][Full Text] [Related]
9. Use of growth hormone in children.
Hindmarsh PC; Dattani MT
Nat Clin Pract Endocrinol Metab; 2006 May; 2(5):260-8. PubMed ID: 16932297
[TBL] [Abstract][Full Text] [Related]
10. Clinical and humanistic aspects of growth hormone deficiency and growth-related disorders.
Rogol AD
Am J Manag Care; 2011 Dec; 17 Suppl 18():eS4-10. PubMed ID: 22590765
[TBL] [Abstract][Full Text] [Related]
11. Ten years with biosimilar rhGH in clinical practice in Sweden - experience from the prospective PATRO children and adult studies.
Lundberg E; Kriström B; Zouater H; Deleskog A; Höybye C
BMC Endocr Disord; 2020 Apr; 20(1):55. PubMed ID: 32349731
[TBL] [Abstract][Full Text] [Related]
12. Safety and Effectiveness of Omnitrope®, a Biosimilar Recombinant Human Growth Hormone: More Than 10 Years' Experience from the PATRO Children Study.
Pfäffle R; Bidlingmaier M; Kreitschmann-Andermahr I; Land C; Partsch CJ; Schwab KO; Sommer H; Backeljauw P; Kanumakala S; Loche S; Zouater H; Strasburger CJ
Horm Res Paediatr; 2020; 93(3):154-163. PubMed ID: 32814319
[TBL] [Abstract][Full Text] [Related]
13. GH and IGF-1 Replacement in Children.
Pfäffle R; Kiess W
Handb Exp Pharmacol; 2020; 261():67-86. PubMed ID: 31932988
[TBL] [Abstract][Full Text] [Related]
14. Growth response to growth hormone (GH) treatment in children with GH deficiency (GHD) and those with idiopathic short stature (ISS) based on their pretreatment insulin-like growth factor 1 (IGFI) levels and at diagnosis and IGFI increment on treatment.
Soliman A; Rogol AD; Elsiddig S; Khalil A; Alaaraj N; Alyafie F; Ahmed H; Elawwa A
J Pediatr Endocrinol Metab; 2021 Oct; 34(10):1263-1271. PubMed ID: 34291621
[TBL] [Abstract][Full Text] [Related]
15. Effect of long-term recombinant growth hormone therapy in children--the National Cooperative Growth Study, USA, 1985-1994.
Root AW; Kemp SF; Rundle AC; Dana K; Attie KM
J Pediatr Endocrinol Metab; 1998; 11(3):403-12. PubMed ID: 11517956
[TBL] [Abstract][Full Text] [Related]
16. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope
Backeljauw P; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
J Pediatr Endocrinol Metab; 2021 Apr; 34(4):431-440. PubMed ID: 33647196
[TBL] [Abstract][Full Text] [Related]
17. [Effect of recombinant human growth hormone on glucose metabolism in children with growth hormone deficiency].
Liang L; Zou CC; Li Y; Wang CL; Jiang YJ; Dong GP; Fu JF; Wang XM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):657-61. PubMed ID: 17217656
[TBL] [Abstract][Full Text] [Related]
18. [Use of growth hormone in children and adolescents].
Bergadá I
Medicina (B Aires); 2013; 73(3):272-6. PubMed ID: 23732208
[TBL] [Abstract][Full Text] [Related]
19. Update in growth hormone therapy of children.
Collett-Solberg PF
J Clin Endocrinol Metab; 2011 Mar; 96(3):573-9. PubMed ID: 21378219
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human growth hormone for the treatment of growth disorders in children: a systematic review and economic evaluation.
Takeda A; Cooper K; Bird A; Baxter L; Frampton GK; Gospodarevskaya E; Welch K; Bryant J
Health Technol Assess; 2010 Sep; 14(42):1-209, iii-iv. PubMed ID: 20849734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
